Jagadish Babu Dasari
Jagadish Babu Dasari has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Bini Chhetri Soren
Department of Research and Development, Quanton BioLife Sciences, Ghatsila, Jharkhand, India
4 shared publications- Paola Fiorani
Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133 Rome, Italy
3 shared publications Alessio Ottaviani
Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy
2 shared publicationsBeatrice Messina
Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy
2 shared publicationsSyed Junied
Department of Research and Development, Quanton BioLife Sciences, Ghatsila, Jharkhand, India
2 shared publicationsA. Intorcia
Univ Roma Tor Vergata, Div Cardiol, Rome, Italy
1 shared publication
Latest Publications
- 23 June 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-21
Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis
Introduction: Malaria is a fatal disease affecting millions of people worldwide, primarily due to infection by Plasmodium falciparum. The emergence of multidrug-resistant parasite strains has necessitated the exploration of novel therapeutic targets. Plasmodium falciparum DNA gyrase A (pfDNA gyrase A), an essential topoisomerase II that is not present in humans, is a promising antimalarial drug target. This study explores the inhibitory potential of three Withania somnifera withanolide derivatives, D, E, and O, against pfDNA gyrase A Methods: An integrated structure-based computational analysis was conducted to explore the inhibitory potential of three withanolides (D, E, and O) against pfDNA gyrase A. Molecular docking, Molecular Dynamics (MD) simulations, and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) free energy calculations were performed. Pharmacokinetic properties were analysed using SWISS ADME and pkCSM tools. Results: Molecular docking revealed high binding affinities for withanolide D (-9.14kcal/mol), E (-9.73kcal/mol), and O (-9.00kcal/mol), with interactions mediated through key catalytic residues, such as GLU648, LYS647, and TRY590, via hydrogen bonding and hydrophobic contacts. MD simulations confirmed the structural integrity and compactness of the complexes through Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration (Rg), and Solvent Accessible Surface Area (SASA). MM/GBSA calculations are further supported by showing the lowest binding free energy for withanolide O and E (ΔGbind =-20.89 and -20.22 kcal/mol). The ADME studies showed favourable pharmacokinetic and physicochemical properties Discussion: This study identifies pfDNA gyrase A as a potential molecular target of Withania somnifera-derived withanolides and elucidates their inhibitory mechanism. Withanolides O and E exhibited strong binding affinity, favorable energetics, and distinct dynamic effects, acting through activesite occlusion and allosteric modulation, respectively. Molecular dynamics and free-energy analyses suggest that effective inhibition results from both structural stabilization and the disruption of critical enzyme motions. Conclusion: Withanolide derivatives were identified as promising inhibitors of pfDNA gyrase A, highlighting their potential as antimalarial agents for addressing drug-resistant malaria.
- 23 June 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-21
Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis
Introduction: Malaria is a fatal disease affecting millions of people worldwide, primarily due to infection by Plasmodium falciparum. The emergence of multidrug-resistant parasite strains has necessitated the exploration of novel therapeutic targets. Plasmodium falciparum DNA gyrase A (pfDNA gyrase A), an essential topoisomerase II that is not present in humans, is a promising antimalarial drug target. This study explores the inhibitory potential of three Withania somnifera withanolide derivatives, D, E, and O, against pfDNA gyrase A Methods: An integrated structure-based computational analysis was conducted to explore the inhibitory potential of three withanolides (D, E, and O) against pfDNA gyrase A. Molecular docking, Molecular Dynamics (MD) simulations, and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) free energy calculations were performed. Pharmacokinetic properties were analysed using SWISS ADME and pkCSM tools. Results: Molecular docking revealed high binding affinities for withanolide D (-9.14kcal/mol), E (-9.73kcal/mol), and O (-9.00kcal/mol), with interactions mediated through key catalytic residues, such as GLU648, LYS647, and TRY590, via hydrogen bonding and hydrophobic contacts. MD simulations confirmed the structural integrity and compactness of the complexes through Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration (Rg), and Solvent Accessible Surface Area (SASA). MM/GBSA calculations are further supported by showing the lowest binding free energy for withanolide O and E (ΔGbind =-20.89 and -20.22 kcal/mol). The ADME studies showed favourable pharmacokinetic and physicochemical properties Discussion: This study identifies pfDNA gyrase A as a potential molecular target of Withania somnifera-derived withanolides and elucidates their inhibitory mechanism. Withanolides O and E exhibited strong binding affinity, favorable energetics, and distinct dynamic effects, acting through activesite occlusion and allosteric modulation, respectively. Molecular dynamics and free-energy analyses suggest that effective inhibition results from both structural stabilization and the disruption of critical enzyme motions. Conclusion: Withanolide derivatives were identified as promising inhibitors of pfDNA gyrase A, highlighting their potential as antimalarial agents for addressing drug-resistant malaria.
- 1 January 2020
- Vol. 8 (4) , 366-375
Swapping of The N-Terminal Domain of Human Topoisomerase 1B with the Corresponding Plasmodium Falciparum Counterpart Strongly Impairs Enzyme Activity
Background: DNA topoisomerases 1B are a class of ubiquitous enzyme that solves the topological problems associated with biological processes such as replication, transcription and recombination. Numerous sequence alignment of topoisomerase 1B from different species shows that the lengths of different domains as well as their amino acids sequences are quite different. In the present study a hybrid enzyme, generated by swapping the N-terminal of Plasmodium falciparum into the corresponding domain of the human, has been characterized. Methods: The chimeric enzyme was generated using different sets of PCR. The in vitro characterization was carried out using different DNA substrate including radio-labelled oligonucleotides. Results: The chimeric enzyme displayed slower relaxation activity, cleavage and re-ligation kinetics strongly perturbed when compared to the human enzyme. Conclusions: These results indicate that the N-terminal domain has a crucial role in modulating topoisomerase activity in different species.
- 1 January 2020
- Vol. 8 (4) , 366-375
Swapping of The N-Terminal Domain of Human Topoisomerase 1B with the Corresponding Plasmodium Falciparum Counterpart Strongly Impairs Enzyme Activity
Background: DNA topoisomerases 1B are a class of ubiquitous enzyme that solves the topological problems associated with biological processes such as replication, transcription and recombination. Numerous sequence alignment of topoisomerase 1B from different species shows that the lengths of different domains as well as their amino acids sequences are quite different. In the present study a hybrid enzyme, generated by swapping the N-terminal of Plasmodium falciparum into the corresponding domain of the human, has been characterized. Methods: The chimeric enzyme was generated using different sets of PCR. The in vitro characterization was carried out using different DNA substrate including radio-labelled oligonucleotides. Results: The chimeric enzyme displayed slower relaxation activity, cleavage and re-ligation kinetics strongly perturbed when compared to the human enzyme. Conclusions: These results indicate that the N-terminal domain has a crucial role in modulating topoisomerase activity in different species.
- 1 March 2019
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 663, 165-172
The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance
- 1 March 2019
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 663, 165-172
The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance
- Open Access
- 1 January 2019
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 3 (1) , 18-25
Topoisomerase IB: a relaxing enzyme for stressed DNA
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.
- 1 January 2019
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 3 (1) , 18-25
Open AccessTopoisomerase IB: a relaxing enzyme for stressed DNA
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.
- 1 December 2018
- Vol. 22 (23) , 8502-8508
Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study
OBJECTIVE: The aim of the study was to examine the safety and efficacy of dronedarone in patients with a history of atrial fibrillation and amiodarone-induced hyperthyroidism. PATIENTS AND METHODS: We conducted a prospective study to evaluate the use of amiodarone and dronedarone in 124 patients with a history of paroxysmal atrial fibrillation who had no additional structural heart disease. All patients received amiodarone 200 mg qd. Out of 124 patients, 56 (45%) switched to dronedarone 400 mg bid due to amiodarone-induced hyperthyroidism and the remaining 68 patients (55%), with normal thyroid function, continued to receive amiodarone. The follow-up period was 12 months, and the patients were regularly monitored. RESULTS: The primary outcome after 6 months dronedarone and amiodarone group was 56 and 68. including 38 (68%) and 54 (79.4%) (Odds ratio [OR] = 1.17, 95% confidence interval [95% CI] = 0.68-2.02) patients with sinus rhythm (SR) and 18 (32.14%) and 14 (28.6%) (odds ratio [OR] = 0.64, confidence interval [95% CI] = 0.29-1.40) patients with atrial fibrillation (AF). The secondary outcome after 12 months showed significant difference in thyroid function in the dronedarone group. Out of 46 patients, 24 (56.18%) patients reduced hyperthyroidism compared to the amiodarone group: out of 68, 6 (8.9%) patients were observed to have hyperthyroidism. At 12 months, there were 24 (43%) and 22 (62%) (odds ratio [OR] = 0.75, confidence interval [95% CI] = 0.38-1.49) patients with SR, and 32 (57%) and 26 (38%) (odds ratio [OR] = 0.67, confidence interval [95% CI] = 0.36-1.25) patients with AF. CONCLUSIONS: In our study, dronedarone appears to be a good therapeutic option in the treatment of atrial fibrillation in patients with amiodarone-induced hyperthyroidism. However. long-term studies are needed to estimate the efficacy and toxicity of both drugs.
- 1 December 2018
- Vol. 22 (23) , 8502-8508
Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study
OBJECTIVE: The aim of the study was to examine the safety and efficacy of dronedarone in patients with a history of atrial fibrillation and amiodarone-induced hyperthyroidism. PATIENTS AND METHODS: We conducted a prospective study to evaluate the use of amiodarone and dronedarone in 124 patients with a history of paroxysmal atrial fibrillation who had no additional structural heart disease. All patients received amiodarone 200 mg qd. Out of 124 patients, 56 (45%) switched to dronedarone 400 mg bid due to amiodarone-induced hyperthyroidism and the remaining 68 patients (55%), with normal thyroid function, continued to receive amiodarone. The follow-up period was 12 months, and the patients were regularly monitored. RESULTS: The primary outcome after 6 months dronedarone and amiodarone group was 56 and 68. including 38 (68%) and 54 (79.4%) (Odds ratio [OR] = 1.17, 95% confidence interval [95% CI] = 0.68-2.02) patients with sinus rhythm (SR) and 18 (32.14%) and 14 (28.6%) (odds ratio [OR] = 0.64, confidence interval [95% CI] = 0.29-1.40) patients with atrial fibrillation (AF). The secondary outcome after 12 months showed significant difference in thyroid function in the dronedarone group. Out of 46 patients, 24 (56.18%) patients reduced hyperthyroidism compared to the amiodarone group: out of 68, 6 (8.9%) patients were observed to have hyperthyroidism. At 12 months, there were 24 (43%) and 22 (62%) (odds ratio [OR] = 0.75, confidence interval [95% CI] = 0.38-1.49) patients with SR, and 32 (57%) and 26 (38%) (odds ratio [OR] = 0.67, confidence interval [95% CI] = 0.36-1.25) patients with AF. CONCLUSIONS: In our study, dronedarone appears to be a good therapeutic option in the treatment of atrial fibrillation in patients with amiodarone-induced hyperthyroidism. However. long-term studies are needed to estimate the efficacy and toxicity of both drugs.
- Open Access
- 27 April 2015
- Published by Gulf Index Electronic Publisher in Pharmacology, Toxicology and Biomedical Reports
- Vol. 1 (1) , 10-13
Impact of Microbial Culture Analysis and Prophylactic use of Antibiotics in Acute Severe Pancreatitis
- 27 April 2015
- Published by Gulf Index Electronic Publisher in Pharmacology, Toxicology and Biomedical Reports
- Vol. 1 (1) , 10-13
Open AccessImpact of Microbial Culture Analysis and Prophylactic use of Antibiotics in Acute Severe Pancreatitis
- Open Access
- 1 January 2014
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 3 (3) , 460-464
Comparative study of pantoprazole and esomeprazole for erosive gastroesophageal reflux disease: a prospective study
- 1 January 2014
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 3 (3) , 460-464
Open AccessComparative study of pantoprazole and esomeprazole for erosive gastroesophageal reflux disease: a prospective study